Related Research Articles
Rheumatology is a branch of medicine devoted to the diagnosis and therapy of rheumatic diseases. Physicians who have undergone formal training in rheumatology are called rheumatologists. Rheumatologists deal mainly with immune-mediated disorders of the musculoskeletal system, soft tissues, autoimmune diseases, vasculitides, and inherited connective tissue disorders.
Rheumatism or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions.
Juvenile idiopathic arthritis (JIA), is the most common, chronic rheumatic disease of childhood, affecting approximately one per 1,000 children. Juvenile, in this context, refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint.
Tadamitsu Kishimoto is a Japanese immunologist known for research on IgM and cytokines, most famously, interleukin 6.
Barbara Mary Ansell, CBE, FRCP, FRCS was the founder of paediatric rheumatology. Ansell was notable for outstanding contributions to the advancement of paediatric knowledge, specifically defining chronic joint disorders and the improvement of their management.
Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.
Childhood arthritis, is any form of chronic arthritis or chronic arthritis-related conditions which affects individuals under the age of 16. It is an autoimmune disease.
The Arthritis Foundation is a nonprofit organization that is dedicated to addressing the needs of people living with arthritis in the United States. There are more than 50 million adults and 300,000 children living with arthritis, the nation's leading cause of disability. The Foundation works to provide information and resources, access to care, advancements in science and community connections.
Oligoarthritis is defined as arthritis affecting two to four joints during the first six months of disease.
Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of fevers, joint pain, and a distinctive salmon-colored bumpy rash. The disease is considered a diagnosis of exclusion. Levels of the iron-binding protein ferritin may be extremely elevated with this disorder. AOSD may present in a similar manner to other inflammatory diseases and to autoimmune diseases, which must be ruled out before making the diagnosis.
Asia Pacific League of Associations for Rheumatology (APLAR) is a federation of organizations of rheumatology. It was established in Sydney in 1963 and the first Congress was held in 1968 in Mumbai at the iconic Taj Mahal Palace Hotel.
Ilar may refer to:
The German Center for Pediatric and Adolescent Rheumatology in Garmisch-Partenkirchen is the largest specialized center for the treatment of children and adolescents with rheumatic diseases and chronic pain syndromes in Europe.
Systemic-onset juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis (JIA) with extra-articular manifestations like fever and rash apart from arthritis. It was originally called systemic-onset juvenile rheumatoid arthritis or Still's disease.
PANLAR, the Panamerican League of Associations for Rheumatology is an association of Rheumatology professional bodies from member nations of North, Central and South Americas.
AFLAR, the African League of Associations for Rheumatology is an organisation of member Rheumatology professional bodies from the African continent and is a partner in ILAR, International League of Associations of Rheumatology. AFLAR publishes the African Journal of Rheumatology twice a year.
WHO celebrated 1977 as the World Rheumatism year and this resulted in a dialogue between ILAR and WHO that led to the idea of COPCORD, Community Oriented Program for Control of Rheumatic Diseases as a joint project between WHO and ILAR. COPCORD promotes low cost epidemiological research in developing countries and has contributed to the understanding of disease burden in data poor regions It has centers in 21 developing countries and has resulted in 102 peer reviewed international publications.
Amita Aggarwal is an Indian clinical immunologist, rheumatologist and a Professor and Head at the Department of Clinical Immunology and Rheumatology of the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. Known for her studies in autoimmune rheumatic diseases, Aggarwal is a recipient of the Shakuntala Amir Chand Award of the Indian Council of Medical Research and an elected fellow of the National Academy of Sciences, India, National Academy of Medical Sciences and the National Academy of Medical Sciences. The Department of Biotechnology of the Government of India awarded her the National Bioscience Award for Career Development, one of the highest Indian science awards, for her contributions to biosciences in 2004.
Ross E. Petty is a Canadian pediatric rheumatologist. He is a professor emeritus in the Department of Pediatrics at the University of British Columbia and a pediatric rheumatologist at BC Children’s Hospital in Vancouver, Canada. He established Canada’s first formal pediatric rheumatology program at the University of Manitoba in 1976, and three years later, he founded a similar program at the University of British Columbia.
References
- ↑ Boers, M; Tugwell, P; Felson, DT; van Riel, PL; Kirwan, JR; Edmonds, JP; Smolen, JS; Khaltaev, N; Muirden, KD (Sep 1994). "World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials". J Rheumatol Suppl. 41: 86–9. PMID 7799394.
- ↑ "Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients". Rheumatology. Oct 2002. Archived from the original on 2011-01-21.